Analytical Data
-
Gene name
GNb3
- Application
-
Alternative Names
Guanine Nucleotide Binding Protein Beta Polypeptide 3; Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3; Transducin beta chain 3
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P16520
-
Expression Region
Met1~Ala257
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GNb3 is a monoclonal antibody that targets the human immune checkpoint protein programmed cell death protein 1 (PD-1), which plays a crucial role in regulating immune responses. The research surrounding GNb3 has gained significant attention due to PD-1's involvement in cancer progression and immune evasion by tumors. By inhibiting PD-1, GNb3 is designed to enhance T-cell activation and proliferation, thereby enabling the immune system to more effectively recognize and destroy cancer cells. This has crucial implications for immunotherapy, as PD-1 inhibitors have demonstrated substantial efficacy in various malignancies, including melanoma and non-small cell lung cancer. The development of GNb3 also aligns with the growing interest in personalized medicine, as it may be tailored to target specific patient populations based on their unique tumor profiles and immune landscapes. Preclinical studies have shown promising results, paving the way for clinical trials and further exploration of GNb3’s therapeutic potential. Overall, the research on GNb3 and its implications in cancer treatment underscores the importance of immune modulation in fighting cancer and highlights the ongoing need for novel therapeutic strategies.
